Results of clinical, pharmacokinetic, and pharmacodynamic studies of 6-azauridine.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001772:Blood Cell Count; D001798:Blood Proteins; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002118:Calcium / Q000378:metabolism; D002642:Chick Embryo; D002784:Cholesterol / Q000378:metabolism; D002822:Choriocarcinoma / Q000188:drug therapy; D005228:Fatty Acids, Essential / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005260:Female; D005333:Fetus / Q000187:drug effects*; D005919:Glomerular Filtration Rate; D006801:Humans; D006828:Hydatidiform Mole / Q000188:drug therapy; D011247:Pregnancy; D014227:Triazines / Q000627:therapeutic use* / Q000633:toxicity; D014498:Uracil / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001798:Blood Proteins; D005228:Fatty Acids, Essential; D005230:Fatty Acids, Nonesterified; D014227:Triazines; D014498:Uracil; D002784:Cholesterol; D002118:Calcium